Jiangsu Hengrui Pharmaceuticals Co.,Ltd (JHPCY)
| Market Cap | 53.36B +23.8% |
| Revenue (ttm) | 4.72B +11.6% |
| Net Income | 1.18B +18.7% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 45.33 |
| Forward PE | 36.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 472 |
| Average Volume | 387 |
| Open | 17.65 |
| Previous Close | 17.14 |
| Day's Range | 17.65 - 17.67 |
| 52-Week Range | 16.72 - 17.67 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | Aug 20, 2026 |
About JHPCY
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China. [Read more]
Financial Performance
In 2025, JHPCY's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.
Financial numbers in CNY Financial StatementsNews
Nuobikan Back To Earth After Spectacular Debut
Last year's king of new listings has announced a steady series of positive developments since its December IPO, but investors don't seem to care image credit: Bamboo Works Key Takeaways: Shares of Nuo...
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the "NewCo" business model image credit: Bamboo Works Key Takea...